论文部分内容阅读
目的观察重组人p53腺病毒注射液联合放疗治疗复发性鼻咽癌的疗效及不良反应。方法以我院2005年1月至2006年12月期间收治的30例复发性鼻咽癌患者为研究对象。用非随机分组法将研究对象分为两组:实验组(15例),采用重组人p53腺病毒注射液肿瘤局部多点注射联合放疗;对照组(15例),采用经典放化同步治疗,分别于首次治疗后8周、6月、12月各随访1次,观察两组的疗效差异。通过CT测量肿瘤最大长径以确定肿瘤大小变化,并采用卡氏评分法评估患者生存质量。结果重组人p53腺病毒注射液联合放疗对复发性鼻咽癌疗效满意,治愈率达20%,临床获益率为100%,除发热外,无其他严重不良反应,疗效及患者生存质量均明显优于放化同步治疗。结论重组人p53腺病毒注射液联合放疗治疗复发性鼻咽癌安全、有效。
Objective To observe the efficacy and adverse reactions of recombinant human p53 adenovirus injection combined with radiotherapy in the treatment of recurrent nasopharyngeal carcinoma. Methods Thirty patients with recurrent nasopharyngeal carcinoma admitted to our hospital from January 2005 to December 2006 were enrolled in this study. The subjects were divided into two groups by non-randomized group: experimental group (15 cases), injection of recombinant human p53 adenovirus injection of local multi-point injection combined with radiotherapy; control group (15 cases) The patients were followed up for 1 week, 8 weeks, 6 months and 12 months after the first treatment, respectively. The maximum diameter of the tumor was measured by CT to determine the change of tumor size, and the quality of life of the patients was assessed by the method of Karnofsky’s score. Results Recombinant human p53 adenovirus injection combined with radiotherapy was effective in treating recurrent nasopharyngeal carcinoma with a cure rate of 20% and a clinical benefit of 100%. In addition to fever, no other serious adverse reactions were found, and the efficacy and quality of life were significantly improved Better than radiotherapy synchronization. Conclusion Recombinant human p53 adenovirus injection combined with radiotherapy for the treatment of recurrent nasopharyngeal carcinoma is safe and effective.